issue, and while chimeric studies where not performed, these could provide interesting information in future cases. Moreover, the presence of background immunosuppression related to the first transplant may create a favorable environment for intestinal engraftment on one hand and may increase the chance of early postoperative life-threatening infectious complications on the other, which represent a common cause of death in these patients. Lastly, from a regulatory perspective, the liver-first approach could potentially interfere with the current liver allocation algorithm and therefore require a more specific deliberation should this practice become more accepted.
In conclusion, sequential split liver followed by isolated intestinal transplant was a safe and feasible approach in our experience and could represent a viable option when timing is crucial.
Ahmed Nassar T ransplantation across antibody barriers has become routine in many centers, with increasingly improved short-to medium-term results. This has coincided with significant technical developments in testing for HLA-specific antibodies; extensive guidelines have been published on how to detect and characterize these antibodies and use this information clinically (1, 2) . In contrast, there has been little corresponding development in ABO antibody testing.
ABO-incompatible (ABOi) live donor kidney pairs are assessed according to risk based on antibody level, and high-risk patients (depending on local policy) are placed in paired exchange programs. However, group O recipients have a lower chance of matching in the current paired exchange program in the United Kingdom.
The testing of ABO-specific antibody is not standardized between transplant centers. Currently, all centers use hemagglutination (HA) methods developed for pretransfusion compatibility testing. There is consensus in published data demonstrating significant variation in titers with different HA techniques between transplant centers (3). The UK National External Quality Assessment Scheme is currently conducting pilot studies across all centers performing ABO HA titration.
HA assays determine an activityspecific (i.e. agglutination) rather than quantify-specific immunoglobulin and, in principle, may not be appropriate in the transplant setting where donorspecific antibody quantification is needed. Initial data associate ABO-specific IgG levels with poorer outcomes, but the different roles of isotypes and IgG subclasses have not been well described (4) . Flow cytometric techniques are beginning to address these questions (5, 6) . Synthetic antigen-binding assays have the potential to provide a more detailed analysis of ABO antibodies but have yet to demonstrate sufficient specificity (7). There is no gold standard test; however, an HA reference technique and a standard reagent to compare each assay against are under development to improve reproducibility and precision between centers.
The implications for not having a standardized assay include poor allograft outcome, listing for paired exchange programs unnecessarily, and excessive desensitization. The UK registry 3-year ABOi kidney allograft survival is lower than ABO-compatible (88% vs. 94%) and lower than internationally published single-center experience (88% vs. 92.9%) (8). Using non-standardized testing causes considerable variability in the ABO titer targets used for clinical decision making and may play a role in poorer allograft outcomes. The growth in the number of ABOi transplant centers in the United Kingdom, basing their practice on protocols at other centers, but with variation in local technique may find different ABO titer results. Whereas a standard protocol for ABO titration is desired, there is no evidence yet to demonstrate the effect of titer variation on clinical outcomes. In a three-center study, a standard method was compared to local results; however, no clinical outcomes were correlated with differences in titer values (9).
We performed a survey of 14 UK centers undertaking ABOi transplantation (n=359 transplants). The median IgG HA titers that clinicians would accept patients onto the ABOi program for treatment was 512 (range, 128Y4096). The median target for acceptable titer on the day of transplantation was 8 (range, 2Y16). These centers had up to a fivedilution titer difference from National External Quality Assessment Scheme data comparing in-house techniques in the respective laboratories; reduced to 1 dilution using a reference technique (see Fig. 1 ). Variation in local in-house titer results did not correspond to acceptable titers onto ABOi programs.
Adoption of a reference technique should give equivalent access to transplantation regardless of geographical area if a live donor pair are ABO-incompatible and not restricted by potentially locally high titers, and conversely, locally low titers might explain higher allograft loss.
Our data demonstrate that there is a wide range in the titers that each center accepts, and discrepancy between local centers will reduce the opportunity for recipients to be entered into an ABOi kidney transplant program. Whereas centers using local titer results are confident in their results, implementation of a reference technique across laboratories would allow comparison of titers between transplant centers and at least facilitate discussions to be had with patients regarding risk and referral to other center that might accept higher titers. It will enable better evidencebased techniques for minimizing risk in ABOi transplantation to be developed in multicenter studies. We suggest that, to provide equality of access and timely transplantation across the United Kingdom, and equally worldwide, a reference technique and antibody standard should be implemented. However, to distinguish between the higher-titer patients who experience early antibodymediated rejection and those who have good allograft outcomes, a quantitative assay may be required as one aspect of improved clinical care. A, blood supply of the rat femur, superior view of the graft. B, blood supply of the rat femur, inferior view of the graft. MCFA, medial circumflex femoral artery; LCFA, lateral circumflex femoral artery; NA, nutrient artery; PA-SCIA, periosteal artery from superficial circumflex iliac artery; PA-HGA, periosteal artery from highest genicular artery; HGA, highest genicular artery; MGA, middle genicular artery; LSGA, lateral superior genicular artery. C, differences in blood supply between the side with ligation of the nutrient artery (NA; left) and the contralateral side (right) in the same rat, after contrast agent perfusion. D, micro-CT scanning of the same femurs in C. E, first kind of NA that arises from superficial circumflex iliac artery. F, second type of NA that arises from lateral circumflex femur artery.
